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It is now clear that there are two types of T lymphocytes. Classical T cells
recognize non-self antigens in the context of molecules of the MHC by means
of the TCR, consisting of disulphide-linked a and (3 chains (1-3). A recently
defined type of T cells, of which it is unclear what they recognize, uses a TCR
encompassing the 'y chain (4, 5). All three chains, a, ,Q, and 'y, have a variable
and a constant domain, encoded in different gene segments that join through
rearrangement during T cell ontogeny (6-8). As compared with TCR-a and 0-
genes, the germline diversity of the TCR--y gene is more limited (9). The human
genome contains 11 variable, 5 joining, and 2 constant (C) gene segments in
tandem (10-12). The 'y gene is rearranged and expressed at an early stage in T
cell development, coinciding with or preceding rearrangement and expression
of respectively TCR-,Q and TCR-a genes (13-15). The TCR--y chain forms either
disulphide-linked or non-disulphide-linked dimers with the so-called 6 protein,
which is structurally distinct from y (16). The gene encoding this protein is posi-
tioned in the TCR-a locus (17) and thus organized in a similar fashion as a, /3,
and y genes, but its exact genomic organization has not yet been unravelled.
Before cell surface expression, either type of TCR associates with the CD3 pro-
tein complex, consisting of four invariant subunits (18, 19), which may play a
role in signal transduction (20).
Upon in vitro activation, TCR-y/S-expressing cells can exert MHC nonre-
stricted cytolytic activity towards allogeneic cells (21-23). In this and other func-
tional aspects, TCR-y/b+ cells share features with CD3- NK cells. On the other
hand, they share features with CD3+/TCR-a/0' MHC-restricted cells in the
expression of CD3 and a potentially variable receptor.
The existence of the TCR--y protein has first been demonstrated biochemically
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using antipeptide sera, reactive with denatured protein . It was found in periph-
eral blood (PB)' of normal individuals on cells derived from a small subset of
CD3 +4- 8 - cells (4, 21, 24) and on CD3 +4-8- thymocytes in both mouse and
man (5, 25), which represent a small population in adults . Human TCR-y/b has
first been identified on CD3+ lymphocytes, which failed to react with the mAb
WT31 (26), thought to recognize a common determinant on TCR-a/(3 . Thus,
TCR-7/6' cells may be identified using CD3 expression and lack of reactivity
with WT31 mAb as criteria . However, it was important to make antibodies that
positively identify TCR-,y/6-expressing cells, particularly since we have recently
found that TCR-,y/6' cells may bind WT31 mAb under certain conditions (26a) .
We here report an mAb, which reacts with human TCR-7/6 in native as well as
denatured states . This is in contrast to previously reported antipeptide sera,
which exclusively detected TCR-y/b after denaturation . With this reagent one
can assess TCR-y/b expression in lymphoid tissues and blood, isolate TCR-y/b
expressing cells, manipulate their function and use it for isolation of the protein :
studies needed to elucidate the role TCR- ,y/6' cells play in the immune system .
Materials and Methods
Cells .
￿
PB samples were derived from healthy volunteers or from children hospitalized
for afflictions other than infectious diseases or disorders of the immune system . Thy-
mocyte samples were from children undergoing cardiac surgery and from an 18-wk-old
human fetus (abortion on medical indication) . These human samples were obtained with
permission of the Committee of Medical Ethics of the Hospital Dijkzigt, Erasmus Uni-
versity, Rotterdam, The Netherlands . PBL were isolated from blood by density separa-
tion using Ficoll-Hypaque . Cloned lymphocytes were generated from PB of normal indi-
viduals in the case of AK 4, AK 781 (donor X ; 22), 1012 (donor Y) and JS-93,-132,-228
(donor JS ; 27), from pleura exudate of a patient with a mamma carcinoma in the case
of AK 119, from PB of a patient with Ty lymphocytosis in the case of NK 77 (28), and
from PB of a patient with subacute sclerosing encephalitis in the case of Wi.K (29) .
Clones AK 4, AK 781 and AK 119 were derived from PBL directly by limiting dilution,
clone 1012 was derived from CD4-8 - sorted PBL of donor Y, clone JS-228 was derived
from WT31 - sorted PBL of donorJS . All clones were cultured in Yssel's medium (30),
supplemented with 2% pooled human serum in round-bottom microwell plates (Greiner
Labor Technik, Plidelsheim, FRG) in the presence of PHA, irradiated allogeneic PBL
and EBV-transformed B cells of the lineJY (feeder cells), as described in detail elsewhere
(31) . The JY line (HLA-A2,2 ; B7,7 ; DR4,w6) was cultured in Yssel's medium supple-
mented with 2% pooled human serum . The human T leukemic cell line PEER (32), the
Burkitt's B lymphoma cell line Daudi, the melanoma cell line MEWO, and the erythroid/
myeloid cell line K562 were cultured in Iscove's medium containing 5% FCS under stan-
dard conditions .
Antibodies.
￿
The purified mAbs WT32 (IgG2a) (anti-CD3) and WT31 (IgGl) used for
immunofluorescence, were kindly provided by Dr . W. Tax, Nijmegen, The Netherlands .
Purified anti-CD3, -CD4, and -CD8 mAbs anti-Leu-4, -Leu-3a, and -Leu-2a, as well as
phycoerythrin (PE)-conjugates of anti-Leu-4, -Leu-3a, -Leu-2a, and goat anti-mouse Ig
were from Becton Dickinson & Co ., Mountain View, CA. For immunoprecipitation of
CD3/TCR complexes the anti-CD3 mAb 2G3 (IgGl) was used, which was a kind gift
from Dr . Chang Geanwu, Dr . L . Willems Instituut, Diepenbeek, Belgium. Anti-Cy serum
was raised in rabbits against a synthetic peptide encompassing amino acids 137-157 of
the human TCR-y protein (4) and was kindly provided by Dr. J . G . Seidman, Harvard
Medical School, Boston, MA .
' Abbreviations used in this paper: IPB, immunoprecipitation buffer ; PB, peripheral blood .BORST ETAL .
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Immunization Protocol and Generation of Hybridomas. For immunization, anti-CD3
immunoprecipitates were prepared as described below from a digitonin-solubilized mix-
ture of cloned cells expressing disulphide-linked TCR-'Y/b . Antigen derived from 50 X
10 6 cells in the form of protein A-Sepharose/anti-CD3/antigen complex was injected
subcutaneously into BALB/c mice three times at 4-6-wk intervals . The fourth injection
was done 7 wk after the third, directly into the spleen, using the same immunogen. The
spleen was removed 4 d later. Spleen cells were fused to myeloma cells of the line SP2/
0 at a ratio of 4:1 using polyethylene glycol . Hybridomas were seeded into 96-well micro-
titer plates (Costar, Cambridge, MA) at 105 spleen cell equivalents per well and grown
and selected under standard conditions (hypoxanthin-aminopterin-thymidin selection) .
Enzyme-linked Immunosorbent Assay (ELISA).
￿
ELISA was used for screening of reactiv-
ity of hybridoma supernatants with intact cells : cells were fixed in microwells using poly-
t.-lysine and 0.025% glutaraldehyde . Specific binding of mAbs to the cells was deter-
mined by incubation with biotinylated horse anti-mouse Ig, followed by incubation with
biotinyl-peroxidase/avidin complex (Vector Inc ., Burlingame, CA) and addition of 5-ami-
nosalicylic acid as a substrate and H 202 as a catalyst .
Immunofluorescence .
￿
Hybridoma supernatants were screened by indirect immunoflu-
orescence using FITC-conjugated goat anti-mouse F(ab)2 Ig (Tago, Inc ., Burlingame,
CA) for staining and a fluorescence microscope for evaluation. For identification and
phenotyping of TCR-y/S+ cells in PB and thymus of normal individuals described in
Table IV, PBL were first incubated withWT31 or anti-TCR-7/6-1 mAb followed by tetra-
methylrhodamine isothiocyanate-conjugated goat anti-mouse Ig. Free binding sites of
the second-step reagent were blocked with normal mouse serum and cells were incubated
with FITC-conjugated mAb directed against CD3, CD4, or CD8 (Becton Dickinson &
Co.) . Samples were analyzed by fluorescence microscopy. For determination of the per-
centages CD3+ , WT31 + , and anti-TCR-y/S-1 + cells, 1,000 cells were inspected for each
sample . For determination of the CD4/CD8 phenotype, 100 anti-TCR-y/S-1 + cells were
inspected for each sample . As a control, normal mouse Ig was used as the first-step
reagent . Other analyses were performed as indicated in the legends of the appropriate
figures .
Cytotoxicity Assays .
￿
Assays were carried out in serum-free medium . Cytotoxicity was
measured in triplicate as percentage of "Cr-release in a 4-h assay using round-bottom
microtiter plates (Greiner Labor Technik) . Effector cells were incubated with anti-TCR-
y/S-1 mAb for 1 h at 37°C before the assay at a dilution of ascites fluid of 1 :100 for
induction or inhibition of cytotoxicity . The antibody remained present during the assay
at a dilution of ascites fluid of 1 :200 .
Radiolabeling.
￿
For cell surface radioiodination ^-20 X 10 6 viable cells were washed
with and resuspended in PBS, and labeled with 1-2 mCi Na
1251 (Amersham Co ., Amer-
sham, United Kingdom) using 1,3,4,6 tetrachloro-3a,6a-diphenyl glycoluril (lodogen ;
Pierce Chemical Co ., Rockford, IL) as a catalyst .
Immunoprecipitation.
￿
Cells were lysed in immunoprecipitation buffer (IPB), consisting
of 0.01 M triethanolamine-HCI, pH 7.8, 0.15 M NaCI, 5 mM EDTA, 1 mM PMSF, 0 .02
mg/ml ovomucoid trypsin inhibitor, 1 mM TLCK, 1 mM TPCK, 0.02 mg/ml leupeptin,
supplemented with either 1% digitonin or 1% NP-40 as detergents . Nuclear debris was
removed by centrifugation for 15 min at 13,000 g . Lysates were centrifuged for 30 min
at 100,000 g and precleared by three subsequent incubations with 30 Al of a 10% vol/
vol suspension of protein A-CL 4B Sepharose beads (Pharmacia, Uppsala, Sweden)
coated with normal mouse Ig. Specific immunoprecipitation was carried out for 2-4 h
with mAb, coupled covalently to protein A beads by means of dimethylpimelimidate-HCI
(Pierce Chemical Co .) . Beads were subsequently subjected to five washes in IPB with
digitonin or NP-40 and samples were analyzed on 10-15% SDS-polyacrylamide gradient
gels . Autoradiography was done using Kodak XAR-5 film in combination with intensifier
screens (Cronex ; Dupont Chemical Co ., Newtown, CT) .
Electronmicroscopy . PBL were obtained from a normal donor . One-half of the cell
sample was incubated with 0 .01 mg/ml purified WT31 mAb and one-half with a 1 :250
dilution of anti-TCR-y/S-1 ascites fluid, followed by washing and incubation with purified1628
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rabbit anti-mouse Ig. Next, cells were washed and labeled with protein A-colloidal gold
probes (9 nm) . Gold particles were prepared by the tannic acid/citrate reduction pro-
cedure (33) and complexed to protein A (Pharmacia) . All incubations were performed
for 30 min at 4°C in the presence of sodium azide . Subsequently, cells were washed with
ice-cold medium and fixed in a mixture of paraformaldehyde (2% wt/vol) and glutaral-
dehyde (2 .5% vol/vol) in 0.1 M sodium cacodylate, pH 7.4, for 24 h at 4°C . Cells were
pelleted in 3% agar (Agar Noble, Difco Laboratories, Inc ., Detroit, MI) at 80°C . After
postfixation in Os04 (1% wt/vol) in cacodylate buffer for 2 h, slices of agar were rinsed,
dehydrated in graded ethanol, and embedded in Epon 812 using a LKB Ultra Processor
(LKB Produkter, Bromma, Sweden) . Ultrathin sections (70 nm) were cut with an I.KB-
Nova ultramicrotome, contrasted with uranyl magnesium acetate and lead citrate staining
and examined in a JEOL-1200 EX electron microscope (JEOL, Tokyo, ,Japan) .
Results
Generation of TCR-y/8-specific mAb . Human TCR--y/b proteins can be iso-
lated in two ways . The intact CD3/TCR-y/b complex can be recovered with anti-
CD3 mAb from cells solubilized in the mild detergent digitonin (34), or from
cells solubilized after chemical crosslinking of TCR and CD3 components (35) .
In addition, rabbit antisera have been described raised against synthetic peptides
encompassing TCR-y sequences (4, 36) . Such sera only detect TCR-y protein
after denaturation . To prepare mAbs, which would detect TCR-y/b proteins in
cell lysates as well as on intact, viable cells, we chose to immunize mice with
CD3/TCR-y/b complexes isolated from digitonin-solubilized cells . A mixture of
clones, expressing disulphide-linked dimers of TCR-y and b chains, was used .
In the relevant fusion, Ig was detected by ELISA in 344 hybridoma culture
supernatants . These supernatants were assayed for reactivity in immunofluores-
cence with viable cells of clone 1012, which expresses disulphide-linked TCR-
y/b . Only one supernatant contained reactivity with clone 1012, while no fluo-
rescence was observed with the TCR-a/0' clone JS-132 or the EBV-transformed
B cell line JY . This supernatant also specifically reacted with glutaraldehyde-
fixed cells of clone 1012 in ELISA . This hybridoma was subcloned to give a
stable clone, anti-TCR-7/6-1, which was used for further studies . The subclass
of the mAb was IgGl .
Reactivity of Anti-TCR-y/6-1 mAb with Viable Clones of Various Phenotypes.
￿
To
assess the specificity of anti-TCR-y/b-1 rnAb, first its reactivity was tested in
immunofluorescence with PBL of 18 normal donors . Positive PBL ranged from
undetectable to 5% as analyzed with a FACS . Such percentages of reactivity
would be expected for a TCR-y/b-specific mAb, given previous results with
WT31 mAb, and the suggestion that predominantly the small CD3 +4-8- T cell
subset would express TCR-y/b (37) . Next, we determined reactivity in immu-
nofluorescence of anti-TCR-y/b-1 mAb on a number of cloned cells of different
phenotypes, representing different lymphocyte subsets and cells with different
configurations ofTCR-y/b : the NK clone NK 77 (CD3-4-8-), the nonlytic clone
AK 781 (CD3+4-8-/TCR-a/0+), the cytolytic clones JS-132 (CD3 +4 --8+/TCR-
a//3+ , class I MHC specific) and JS-93 (CD3 +4+8 -/TCR-a/0+ , class 11 MHC
specific), and the cytolytic clones Wi.K, JS-228, AK 119, and AK 4 (CD3 +4- 8 - ,
unknown specificity) . It has been shown in immunoprecipitation experimentsusing anti-Cy peptide serum that the latter four clones express the TCR-y pro-
tein, be it in different configurations : non-disulphide-linked (Wi.K, JS-228) or
disulphide-linked (AK 119, AK 4), and without (Wi.K, AK 119) or with (JS-228,
AK 4) direct evidence for participation of a S chain in the receptor (see below) .
Also tested was the T leukemic cell line PEER, which was previously shown to
express a non-disulphide-linked TCR-y chain of ^"55 kD (24, 38), which is a
different molecular mass than found for the TCR-y chains on Wi.K or JS-228
(see below) .
As can be seen in Fig. 1, neither the CD3- NK clone, nor any of the TCR-a/
a E
i
0 aCD3 WT31 CtTCRrS
1 10 100
Fluorescence Intensity-
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FIGURE 1 .
￿
Immunofluorescence of
various representative lymphocyte
clones with anti-TCR--t/S-1 mAb.
Cells were incubated with 0.01 mg/
ml purified WT32 (anti-CD3) or
WT31 mAb, or with anti-TCR--y/6-1
mAb at 1 :500 dilution of ascites
fluid, followed by incubation with
FITC-conjugated goat anti-mouse
F(ab)1 Ig. Fluorescence analysis was
performed usinga FACS IV (Becton
Dickinson & Co., Sunnyvale, CA) .
The characteristics of the cell sam-
ples used are indicated in the text.
Fluorescence intensity is plotted
on a logarithmic scale . For exact
comparison, fluorescence indexes,
defined as : [(fluorescence inten-
sity sample)- (fluorescence inten-
sity negative control)] /(fluorescence
intensity negative control), are
given :
NK77 AK781 JS-132 JS-93 Wi.K JS-228 PEER AK119 AM
31
Anti-CD3 0 15 49 20 8.2 11 4.5
￿
59
WT31 0 9 42 22 1 .3 1 .5 0.3 4.4 7 .8
Anti-TCR-7 0 0.2 0.2 0.2 4 3.5 1 .1 14 43
Il ,
l.-
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a+ clones reacted with anti-TCR-y/b-1 mAb. In contrast, all TCR-y/b-express-
ing clones were positive. For comparison, fluorescence profiles obtained with
anti-CD3 and WT31 mAbs are also shown. Fluorescence intensities are given in
the legend of Fig. 1 . Except NK 77, all clones expressed CD3. TCR-a/0' clones
reacted strongly with WT31 mAb, with intensities comparable to those obtained
with anti-CD3 mAb. TCR-7/6' clones also bound WT31 mAb, but stained at
low intensities, while on these clones fluorescence intensities with anti-TCR-
y/b-1 mAb were more comparable to those obtained with anti-CD3 mAb. These
results clearly indicate that reactivity with anti-TCR-,y/6-1 mAb, rather than lack
of reactivity with WT31 n Ab is a proper criterion for the identification of TCR-
y/S-expressing cells.
Anti-TCR-y/X1 mAb Reacts with Different Molecular Species of TCR-y/ain Immu-
noprecipitation. In contrast to TCR-a/0, TCR-y/b occurs in various molecular
configurations. We have previously described (21) cytolytic clones such as AK 4,
expressing a TCR consisting of a 40-kD y chain disulphide linked to a 43-kD S
chain. Clone 1012 and eight other clones derived from the same culture express
a similar receptor (not shown) . Clone AK 119 was an exception, in that it
expressed a disulphide-linked receptor, including a differentially glycosylated y
chain migrating at 36 and 40 kD, while no S chain could be detected by cell
surface iodination (21). Non-disulphide-linked TCR-y/b have been demon-
strated on a growth factor-dependent cell line derived from PB of an immu-
nodeficiency patient (4), a leukemic T cell line (24, 38), and PBL from a leu-
kemic patient (39). We have derived several T cell clones expressing non-
disulphide-linked TCR-y/b from PB of a normal individual, one of which was
used in these studies (JS-228). In addition, a clone expressing a non-disulphide-
linked receptor has been isolated from PB of a patient with autoimmune disease
(clone Wi.K). Fig. 2 demonstrates the presence of the y chain in the non-disul-
phide-linked CD3-associated receptors found on clones Wi.K (lanes A and B)
and JS-228 (lanes D and E), which was identified by immunoprecipitation with
anti-Cy peptide serum (lanes C and F). The mol mass of the y chain was ^-41
kD for clone Wi.K and ^-44 kD for clone JS-228. This in contrast to the -55-
kD mol mass of the y chain found on the cell line PEER (lanes G, H, and I;
references 24, 38). In cloneJS-228 a b chain could be detected, migrating at 37
kD under nonreducing and 40 kD under reducing conditions (lanes D and E,
arrows). In clone Wi.K a b chain could not be demonstrated by cell surface iodi-
nation. Table I summarizes the different molecular forms of TCR-y (b).
To prove that anti-TCR-y/b-1 mAb reacted with TCR-y/b, we have carried out
reprecipitation experiments. Anti-CD3 immunoprecipitates were prepared from
digitonin solubilized, '25I-labeled TCR-,y/6-expressing clones. Next, TCR-7/6
was dissociated from CD3 by incubation of the immunoprecipitate in buffer with
1% NP-40 and 1% SDS, for 30 min at room temperature. The solubilized mate-
rial was subjected to immunoprecipitation with anti-TCR-7/6-1 as detailed in the
legend of Fig. 3. In Fig. 3 the CD3/TCR-y (b) complexes as isolated by anti-CD3
mAb are shown, as well as TCR-y (b) reprecipitated with anti-TCR-y/b-1 mAb.
The antibody could be used to reprecipitate both types of disulphide-linked
receptors from TCR-y (b)+ clones 1012 (lanes A and B) and AK 119 (lanes C,
D, G, and H), as well as the non-disulphide-linked receptors from TCR-y (b)+
clones Wi.K (lanes E and F) andJS-228 (not shown).FIGURE 2 .
￿
Characteristics of non-disulphide-linkedTCR-y (b) . Cells were labeled with 'zsl,
anti-CD3 immunoprecipitates were made from digitonin lysates and analyzed by SDS-PAGE
under nonreducing (NR) or reducing (R) conditions. For reprecipitation of TCR-y chains,
anti-CD3 precipitates were incubated in IPB with 1% SDS and 2 mM DTTfor 5 min at 68 °C .
The supernatant was diluted five times with IPB containing 1.5% NP-40, 20 mM iodoacet-
amide and 25 ug myoglobin, precleared once with normal mouse Ig-coated beads and sub-
jected to immunoprecipitation with anti-Cy serum . Arrows indicate the positions of the b
chain. (A) Clone Wi.K, anti-CD3, NR ; (B) clone Wi.K, anti-CD3, R; (C) clone Wi.K, anti-Cy,
R; (D) clone JS-228, anti-CD3, NR; (E) clone JS-228, anti-CD3, R; (F) clone JS-228, anti-Cy,
R; (G) PEER, anti-CD3, NR; (Fn PEER, anti-CD3, R; (I) PEER, anti-Cy, R .
Thus, anti-TCR-,y/6-1 mAb reacts with all different types of TCR-y (b)
described thus far, in native state as present on intact viable cells, as well as in
denatured state after detergent solubilization .
Anti-TCR-y/â 1 mAb Affects the Function of Cytolytic Clones .
￿
We have demon-
strated previously (21, 22) that TCR-y (b)-expressing clones can exert cytolytic
BORST ET AL.
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TABLE I
Molecular Forms ofTCR y(ô)
* Occasionally detected.
2 R, reducing conditions ; NR, nonreducing conditions .
Clone Receptor
type
Interchain
S-S bond
Mol mass ofy
chain
kD
Mol mass of b chain
kD
AK 119 y(b) + ^-40+ ^-36 Notdetected
AK 4 y b + ^-40(+ -36)* ^-43
1012 'y 6 + -40(+ ^-36) -43
Wi.K y(b) - ^-41 Not detected
JS-228 'r 6 - ^-44 ^-40 (R), -37
(NR)z
PEER 'r b - ^-55 -40 (R),-37 (NR)1632 T CELL. RECEPTOR y/S DETECTED BY AMONOCLONAL ANTIBODY
FiC3URE 3. Biochemical proof that
anti-TCR-y/S-1 mAb detects TCR-y
(S) . Anti-CD3 precipitates were pre-
pared as described for Fig. 2 . TCR-
y (S) was dissociated from CD3 by
incubation of one-half of the anti-
CD3 precipitates in IPB with 1%
NP-40 and 1% SDS for 30 min at
room temperature . The supernatant
was diluted five times with IPB con-
taining 1 .5% NP-40 and 25 Ag myo-
globin, precleared once with normal
mouse Ig-coated beads, and sub-
jected to immunoprecipitation with
anti-TCR-y/S-1 mAb and analyzed
by SDS-PAGE under nonreducing
(NR) or reducing (R) conditions. (A)
Clone 1012, anti-CD3, R; (B) clone
1012, anti-TCR- ,y/6-1, R; (C) clone
AK 119, anti-CD3, R; (D) clone AK
119, anti-TCR-y/S-l, R; (F_) clone
Wi.K, anti-CD3, R; (H) clone Wi.K,
anti-TCR-y/b-1, R; (G) clone AK
119, anti-CD3, NR; (Fn clone AK
119, anti-TCR-y/6-1, NR .
activity upon in vitro culture, without evidence for involvement of polymorphic
domains of MHC molecules on the target cells . The activity could be regulated
by mAbs directed at CD3, which opened the possibility that the CD3-associated
TCR-y/S was involved in the recognition of these target cells . Another option
would be that the cytotoxic spectrum of the clones did not reflect the specificity
of the receptor and that the effect of anti-CD3 mAb reflected the regulatory
capacity of the TCR-y/d/CD3 complex .
It had been observed that lymphokines, such as IL-2 and IFN-/3 enhanced the
cytotoxicity of TCR- ,y/6-expressing clones (22) . Therefore, it was investigated in
the first place, whether the lymphokines produced by the feeder cell mixture
used to culture TCR-y/b+ clones, affected the cytotoxic potential of the clones.
For this purpose, two TCR- ,y/6-expressing clones, 1012 and Wi.K, were cul-
tured for 5 d in the presence of irradiated feeder cells . Next, when feeder cells
had disintegrated, clones were washed and cultured for an additional 72 h in
Yssel's medium with 2% pooled human serum, lacking lymphokines . To one part
of the cells, deprived of feeder cell factors for 48 h, rIL-2 was added at 1,000
U/ml for 24 h. Control cells of the same batch were kept in culture for 8 d
without changing the medium . Then, cytotoxicity was tested towards four allo-
geneic tumor cell lines of different histological origin . In Table 11 it can be seen
that clone 1012, when harvested directly from the 8-d culture in the presence
of feeder cells and their products (control), displayed significant MHC nonre-
stricted cytotoxicity towards all target cells . The cytotoxicity of factor-deprived
cells of clone 1012 towards three of four target cells was drastically reduced,
while it could be enhanced to a level comparable to or higher than that of con-
trol cells by the addition of IL-2 . Clone Wi.K displayed significant cytotoxicityBORST ET AL.
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TABLE II
Influence of Feeder Cell Factors on the Cytotoxicity of TCR y/8' Clones
* Target cells used.
1 ET cell ratio
§ Control: culture with feeder cells for 8d.
~~ - factors: culture as in "control," but harvested and washed on day five and subsequently cultured
in absence of lymphokines for 72h.
9 + II:2: culture as in "- factors," but cultured with 1,000 U/ml IL-2 during the last 24h.
only towards K562 cells, where similar effects of factor depletion and IL-2 addi-
tion were observed as for clone 1012 . IL-2 could not induce significant cytotox-
icity of Wi.K towards the other three target cell lines.
Secondly, it was determined whether anti-TCR-,y/6-1 mAb affected the func-
tion of the clones. Clones 1012, Wi.K, and as a control, the TCR-a//3+ cytotoxic
clone JS-132, specific for a determinant on the HLA-A2 molecule, were used.
To discriminate between factor-induced cytotoxicity and possible cytotoxicity
reflecting the specificity of the TCR molecules, the assay was carried out with
clones kept in culture with feeder cells for 8 d (control), as well as with clones
harvested and washed on day six and cultured in the absence of lymphokines as
described above, for 48 h. The results of this experiment are shown in Table
III. Clone JS-132 displayed nonspecific cytotoxicity towards K562 and Daudi,
which was strongly reduced in the absence of factors, while its specific activity
towards JY and MEWO involving recognition of HLA-A2 by the TCR was
retained. Again, the effect of factors produced by the feeder cell mixture on the
cytotoxicity of clone 1012 was evident. In this experiment also the cytotoxicity
of clone 1012 towards the cell line Daudi was reduced in the absence of factors,
in contrast to the results shown in Table II . Clone Wi.K did not display any
cytotoxicity in this experiment. However, anti-TCR-y/8-1 mAb induced signifi-
cant cytotoxicity of clone Wi.K towards K562 and Daudi, but not to JY or
MEWO. The antibody had no effect on the cytotoxicity of clone 1012 towards
K562, but reduced its activity towardsJY, Daudi, and MEWO. As expected, anti-
TCR-y/S-1 had no effect on the activity of clone JS-132 .
It is concluded that the MHC-nonrestricted cytotoxicity of TCR-y/S+ clones
1012 and Wi.K is induced by the culture conditions, most likely by growth fac-
tors such as IL-2 produced by the feeder cell mixture. Addition of mAb towards
TCR-y/S can specifically induce cytotoxicity. The antibody can also specifically
Clone
K562*
Percent
JY
cytotoxicity
Daudi MEWO
10:1 1 2:1 10 :1 2:1 10:1 2:1 10:1 2:1
1012: ControlO 52 32 35 26 69 67 39 22
- factorsil 8 0 19 10 73 37 11 2
+ IL-24 66 46 55 44 71 73 53 31
Wi.K: Control 32 9 8 3 4 2 13 3
- factors 7 0 11 3 0 0 1 0
+ IL-2 31 18 13 14 0 0 9 41634
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TABLE III
Influence ofAnti-TCR-y/X1 mAb on the Cytotoxicity of TCR-y/d+ Clones
* Target cells used.
" ET cell ratio.
4 Control: culture with feeder cells for 8d.
~~ - factors: clones harvested and washed on day six and cultured in absence of lymphokines for
48 h.
inhibit cytotoxicity, despite the fact that this activity must be categorized as fac-
tor induced.
Distribution of TCR-y (a)-bearing Cells in Normal PBL and Thymus.
￿
Since we
had demonstrated the reactivity of anti-TCR-y/b-1 mAb with all forms of TCR-
y (b) described thus far, we felt confident to use this antibody to assess the
occurrence of this second type of TCR in PB and thymus of normal individuals .
In an initial experiment described above, using FACS analysis of PBL from 18
normal adult donors, variable percentages of TCR-y/b+ cells had been found,
ranging from undetectable to 5%. In a few cases, including that of donor CM,
a distinct subpopulation of TCR-,y/6' cells could be observed. PBL from this
donor were used to determine the percentage of CD3+/TCR-7/6' cells and the
CD4/CD8 phenotype of this population by two-label immunofluorescence, fol-
lowed by FACS analysis. As can be seen in Fig. 4, 7 .2% of CD3+ cells in this
individual expressed TCR-y/b (panel A). The majority of these cells were of the
CD4- 8 - phenotype as previously described. No TCR-y/b+ cells expressing the
CD4 marker were detectable (panel C) . However, 21% of TCR-y/b+ cells was
CD8 + (panel D) . In Fig. 4 it is also shown that freshly isolated TCR-y/b+ cells
stain very weakly or not with WT31 mAb (panel B) .
To determine the percentage of TCR-y/5+ cells and their phenotype accu-
rately, PBL samples were stained by two-label immunofluorescence and analyzed
by fluorescence microscopy. In these cases, PBL were derived from donors
ranging in age from 2 mo to 16 y in order to investigate whether age affected
the size of the TCR-y/b+ population. In these samples, the percentages of
Clone K562*
10:1 " 2 :1 10:1
Percent
JY
2:1
cytotoxicity
Daudi
10 :1 2 :1
MEWO
10:1 2:1
1020: Control* 37 11 23 10 55 21 42 17
Control + mAb 28 18 7 4 13 5 7 2
- factorsil 0 0 10 5 26 7 11 4
- factors + niAb 10 6 1 1 3 2 1 1
Wi.K: Control 3 0 0 0 2 0 3 1
Control + mAb 57 46 4 2 63 33 13 6
- factors 0 0 0 0 2 1 1 0
- factors + nulb 30 25 0 0 28 13 2 1
JS-132: Control 55 32 88 84 26 9 64 43
Control + mAb 61 38 81 84 36 9 52 47
- factors 15 6 90 86 2 1 54 43
- factors + mAb 20 10 86 81 3 1 48 40w
a
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FIGURE 4. Phenotypic anal-
ysis of TCR-f (S)+ cells in PB
of a normal donor by two-
label immunofluorescence.
PBL were first incubated with
anti-TCR-y/d-I mAb, fol-
lowed by goat anti-mouse Ig-
FITC conjugate (A, C, and D)
or goat anti-mouse Ig-PE
conjugate (B). Free binding
sites of the second-step
reagent were blocked with
normal mouse serum and
cells were incubated with PE-
conjugated mAb (A, C, and
D) or FITC-conjugatedWT31
(B). Fluorescence analysis was
performed using a FACStar
(Becton Dickinson & Co.).
Fluorescence intensities for
all panels are plotted identi-
cally on a `log scale as indi-
cated in A. (A) Anti-Leu-4
(anti-CD3) PE; anti-TCR-f/S-
1 FITC. (B) Anti-TCR-
y/S-1 PE; WT31 FITC.
Anti-Leu-3a (anti-CD4) PE ;
anti-TCR-'Y/S-1 FITC. (D)
Anti-Leu-2a (anti-CD8) PE;
anti-TCR-f/S-1 FITC.
CD3+, WT31 +, and TCR-7/6' cells were determined by examination of 1,000
cells for each marker. The CD4/CD8 phenotypes of TCR-,y/8+ cells were deter-
mined by examination of 100 TCR-,y/6' cells. The results from 10 donors are
enumerated in Table IV. The percentages of TCR-,y/6' cells ranged from 1.9 to
7.2°1o within the CD3+ cell population. The fluorescence of the TCR-y/8+ pop-
ulation was virtually mutually exclusive with the fluorescence of the WT31 + pop-
ulation. In 4 of 10 donors CD4+/TCR--y/5+ cells were detected, constituting up
to 3.0% of TCR-y/S+ cells. In all donors but one, CD8+/T'CR-y/S+ cells were
found, ranging from 1.0 to 17% of TCR-7/6' cells. No obvious correlation
between age of the donor and the size of the TCR-,y/6' population could be
found. In addition, Table IV lists data obtained with thymocytes derived from
three children. The relative size of the TCR--y/5+ population in these thymuses
was significantly smaller than in PBL, ranging from 0.1 to 1.0% of CD3+ cells.
Also, most TCR-^y/S+ thymocytes were of the CD4-8- phenotype, while signifl-
Panel
1
A 64.0
B 3.62
C 45.3
D 20.8
Percent fluorescence
Quadrant
2 3 4
4.58 31 .0 0.50
1.07 31 .4 63.9
0.01 49.7 4.99
1.14 73.8 4.251636
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TABLE: IV
Percentage andPhenotype ofAnti-TCR-y1XI 'Cells in PB and Thymus ofNormal Donors
NT, not tested.
" Fetal thymus.
cantly more CD8+/TCR-y/b+ than CD4+/TCR-y/b+ cells were found. The same
analysis was done for thymocytes derived from an 18-wk-old fetus. At this early
stage in human development, the percentage of TCR-,y/6' thymocytes was 0.7%
of CD3 + cells.
Ultrastructure of TCR-y (8)+ Cells in PB.
￿
To study the morphological features
of TCR-y (b)+ cells in PB, electronmicroscopy was used. PBL were derived from
a healthy individual, who had previously been found by FRCS analysis to contain
a relatively high percentage of TCR-,y/6' cells. To identify these TCR-y/b+ cells
in electron microscopy, the total cell population was stained with anti-TCR-
-y/b-1 mAb, followed by rabbit anti-mouse Ig and gold-conjugated protein A.
For comparison, cells were labeled in the same fashion using WT31 mAb, which
in a freshly isolated PB sample would allow predominantly the identification of
TCR-a/,(3+ cells. The gold labeling was specific as indicated by the fact that 40%
of the cells were labeled using WT31 mAb, while 4% of the cells were labeled
using anti-TCR-y/b-1 mAb, figures corresponding to the results of immunoflu-
orescence stainings. Fig. 5 shows two cells, representative of the anti-TCR-'Y/b-1 +
population (left) or the WT31 } population (right). No significant overall differ-
ences in ultrastructural morphology between these two populations were
observed. Both cell types appeared to be medium sized lymphocytes, -7-8 Am
in diameter. Moreover, like TCR-a/0' cells, TCR-y/b+ cells were resting lym-
phocytes as determined by the following features: a high nucleus/cytoplasma
ratio, a single "resting" nucleolus (not seen in the left hand photo) in a het-
erochromatin-rich nucleus, and a small amount of finely vesicular smooth-sur-
faced membranes; ribosomes existed as single units rather than as polysomal
Donor Age CD3+
WT31 +
per
CD3+
Anti-
TCR-y/6-1 +
per CD3+
CD4+ per anti-
TCR-y/8-1 + CD8 + per anti-
TCR--y/S-1 +
PB % % % % %
samples
HM 2 mo 47 98 1 .9 0 10
PvH 2.5 mo 62 98 1 .9 3 12
WB 3 mo 38 96 2.4 3 17
KD 13 mo 44 94 5.6 0 9
SB 27 mo 38 95 4.7 0 1
MH 6 y 73 98 1 .9 1 5
MJ 7 y 61 90 7.2 0 0
SN 8 y 61 94 3.9 0 6
AvdH 12 y 71 96 4.4 1 1
EH 16 y 63 96 4.1 NT~ 6
Thymus
sample
A 3 wk 76 99.2 1 .0 NT NT
B 5 y 63 99.5 0.2 0 8
C 10 y 73 99.9 0.1 0 28
D" 18 wk- 78 99 .0 0.7 NT NTBORST ET AL.
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aggregates ; rough endoplasmatic reticulum and Golgi system were almost com-
pletely absent and only some small mitochondria and a few lysosomes were
observed . There was no evidence for the presence of significant numbers of
"granular structures" as can be identified in activated cytolytic T cells .
Discussion
An mAb specific for human TCR-y (b) was generated, using as immunogen
CD3/TCR complexes isolated from digitonin-solubilized clones . The major
advantage of this mAb over the already available anti-TCR--y peptide sera is that
it reacts with intact, viable cells . This allows positive identification of TCR-y/b-
expressing cells by immunofluorescence . Previously, human TCR-y/b + T cells
have been identified using lack of reactivity with WT31 mAb as an indication
and immunoprecipitation with anti-Cy peptide serum as confirmation . This pro-
cedure is more time consuming than immunofluorescence, requires a relatively
large number of cells, and is not fail-safe, since TCR-,y/6' cells may react with
WT31 mAb (see above and reference 26a) . Reactivity of anti-TCR- ,y/6-1 mAb
with viable cells also allows their selective isolation from heterogeneous cell pop-
ulations and their subsequent use in functional or biochemical studies .
Unlike TCR-a/a, TCR-y (b) occurs in different molecular configurations . In
the first place, TCR-y (b) can occur in either disulphide-linked or non-disul-
phide-linked forms . The molecular basis of this difference in organization has
been unravelled (16, 39, 40) . Of the two C gene segments in the y locus, C-y-1
encodes a cysteine residue in its second exon, while Cy-2 does not (11) . This
cysteine residue is thought to be responsible for the formation of an interchain
disulphide bond (6). Secondly, significant differences in size of TCR-y chains
are detected between non-disulphide-linked receptors on different cells. The
leukemic line PEER (24, 38) and the line IDP2 (4, 24) express a y chain of
^-55 kD, while on clones Wi.K andJS-228, as well as on PBL from a leukemic
patient (39), we have found a y chain of 40-44 kD . In PEER, a triplication of
the second exon of the C gene segment has occurred, rather than a duplication
as in other cells using Cy-2, which seems to be a polymorphic feature (40) . How-
ever, since this exon contains only 48 bp, this is not sufficient to explain the
size difference between the 55-kD and the 40-44-kD y chains . Posttranslational
modifications of the y chain may play a role . A third aspect in which TCR-y (b)
shows organizational variation, is the appearance of the b chain . In more than
10 clones expressing disulphide-linked receptors analyzed thus far, we have
clearly identified a ^-43-kD b chain (unpublished results) . Clone AK 119 is an
exception in that no b chain can be detected after cell surface labeling with
1151
.
Moingeon et al . (23) have also reported disulphide-linked TCR-y in which no b
chain could be detected . A similar problem is encountered in the analysis of
non-disulphide-linked receptors . In PEER, Weiss et al . (38) observed only a 55-
kD y chain, while Brenner et al . (24) in addition found a b chain that migrated
at 40 kD under reducing conditions and at a lower mol mass under nonreducing
conditions . Such a b chain was also found in the line IDP2 (4). Our results are
consistent with those of Brenner et al . In PEER as well as in clone JS-228
derived from PB of a normal individual a b chain was expressed, which, however,
did not label consistently well by cell surface iodination . In clone Wi.K as wellBORST ET AL.
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as in TCR-y+ leukemic T cells (39) no S chain could be detected by cell surface
labeling with '251. Possibly, the ó chain present in non-disulphide-linked recep-
tors, as well as in the disulphide-linked receptor expressed on clone AK 119,
cannot be labeled efficiently by this technique. However, to account for such
dramatic effect on '25I-labeling this chain must differ significantly in primary
structure and/or conformation from the S chain found in the disulphide-linked
receptors. We are currently investigating the occurrence of the S chain using
metabolic labeling. Preliminary results indicate that all types of receptors con-
tain a ó chain. It should be remarked that it is not known, whether the S chain
in disulphide-linked receptors and the S chain in non-disulphide-linked recep-
tors are products of the same gene.
Anti-TCR-,y/6-1 mAb reacts with all types of TCR-y/S. It is not clear on which
chain of TCR-y/S the epitope recognized by anti-TCR-y/ó-1 mAb is located. The
mAb does not react in Western blotting, nor after separation of either disul-
phide-linked or non-disulphide-linked y and S chains by reductive alkylation
and/or denaturation in SDS at high temperatures. Therefore, this point is dif-
ficult to resolve.
TCR-,y/6-expressing cells can display MHC-nonrestricted cytotoxicity (21-24,
36). As was shown earlier for T cells activated in mixed lymphocyte cultures
(40a) and cloned TCR-a/0+ T cells (40b), and as is shown here for TCR-,y/6' T
cell clones, such cytolytic activity is induced by the culture conditions. Cells are
stimulated weekly with irradiated allogeneic PBL andJY cells, and PHA. Growth
factors are produced, such as IL-2, which previously has been shown to enhance
cytolytic activity of TCR-y/S-expressing clones (22). A TCR-a/0-expressing
clone also displayed MHC-nonrestricted cytotoxicity, which was lost upon factor
depletion. However, its specific activity, dependent on expression of the HLA-
A2 molecule on the target cells, was retained. Similarly, cytotoxicity of TCR-y/
S cells, reflecting the specificity of the receptor, would be expected to remain
after factor depletion, particularly since expression of the receptor is not
affected. Therefore, TCR-y/S most likely does not play a role in target cell rec-
ognition in the case of in vitro-induced MHC-nonrestricted activity, which has
also been suggested by others (41). Recently, evidence has indeed been pre-
sented that MHC molecules may be the ligand of TCR-y/S (42). However, the
receptor plays a role in the regulation of T cell activity in the in vitro systems
used. mAbs directed at the receptor may induce nonspecific cytotoxicity (this
paper and reference 43), and proliferation (23), as shown previously for TCR-
a/0-expressing cells, which is dependent on the presentation of the mAb via Fc
receptors on the target cells (44, 45). Also, inhibition of nonspecific cytotoxicity
was reproducibly found. In one case, cytotoxicity of clone 1012 towards Daudi,
which bears Fc receptors for IgGI, was inhibited, while cytotoxicity of clone
Wi.K was induced. Perhaps the effect depends on the nature of the conforma-
tional change induced in the receptor by binding of the mAb.
It is unknown what contribution TCR-,y/6' cells make to the immune system.
Therefore, it is of interest to determine in which tissues and in what relative
numbers TCR-,y/6' lymphocytes are present in man, in health and disease. In
this paper, we have reported the percentages of TCR-,y/6' cells in PB and thy-
mus of normal individuals . In 11 donors, TCR-y/S+ cells constituted 1 .9-7 .2%1640
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of CD3+ lymphocytes in PB. It has not yet been determined whether these per-
centages are constant with time in a given healthy donor. In thymus samples
from three children, the percentage of TCR-y/b+ thymocytes ranged from 0.1
to 1.0% of CD3+ cells, which is significantly lower than in PB. These data are
consistent with those reported for CD3+/WT31 - cells in PB and thymus (37) .
WT31 expression is indeed very low or nondetectable on freshly isolated TCR-
y/b+ cells. Thymocytes from an 18-wk-old human fetus were included in this
study, since Pardoll et al. (46) had reported the expression of TCR 'Y/b on all
fetal thymocytes at day 15 of gestation in mouse. No higher percentage of TCR-
y/b+ cells were detected in human fetal thymus than in thymi derived from chil-
dren . It may be relevant to study earlier samples.
The phenotype of the majority of TCR-y/b+ cells in PB and thymus was
CD4-8-, in concordance with previously published data. However, in the total
pool of TCR-7/6' cells, as we have been able to study now, a significant pro-
portion may bear the CD8 antigen, ranging from 0 to 28% between 13 donors.
CD8+/TCR-y/b+ clones have indeed been reported (47) . We have found that
CD4+/TCR-,y/6' cells are much more infrequent, but do occur. TCR-y/6' cells
of the CD4+ phenotype have not previously been reported . In two-label immu-
nofluorescence using FACS analysis as well as fluorescence microscopy, we have
observed some TCR-y/b+ cells, which did not react with anti-CD3 mAb.
Although it is an unlikely possibility, it will have to be investigated whether TCR-
y/b can be expressed at the cell surface in the absence of the CD3 molecule .
Electron microscopic analysis has pointed out that TCR-y/b+ cells in PB are
resting lymphocytes, like TCR-a/0' cells and unlike NK cells. This is consistent
with our previous observation that CD3+4-8- cells derived from PB need in
vitro activation in order to become functionally active (48). It will be investi-
gated whether more subtle morphological features discern TCR-y/b+ cells from
TCR-a/0' cells. For instance, CD3+4-8- cells have previously been selectively
isolated on continuous density gradients, which would imply certain differences
in cellular structure (48).
Further studies will involve the identification of human TCR--Y/b+ cells in
healthy and diseased states, their isolation and characterization, in which the
developed mAb will be an important tool.
Summary
A second type of TCR molecule has been identified on human and murine T
lymphocytes, which involves the protein products of the y and b genes. T lym-
phocytes bearing this receptor may constitute a separate cell lineage with a dis-
tinct immune function . We have produced an mAb, which specifically detects
human TCR-7/6 in native as well as denatured states, this in contrast to previ-
ously used anti-y chain peptide sera, which only reacted with denatured protein.
The receptor occurs in different molecular forms, with or without interchain
disulphide bonds, in which a b chain may or may not be detected by cell surface
iodination. The mAb is reactive with all these receptor forms. Therefore, this
antibody could be used to determine the expression of TCR-y/b on viable
human T lymphocytes. In normal individuals, TCR-y/b was found on a subset
composing 2-7% of CD3+ lymphocytes in peripheral blood and 0.1-1 .0% inBORST ET AL.
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thymus. The majority of these cells do not express the CD4 or CD8 antigens,
although a significant percentage of CD8 + cells was found. TCR-'Y/8+ cells in
peripheral blood are resting lymphocytes, as judged by ultrastructural analysis.
T cell clones with different receptor types can display MHC-nonrestricted cyto-
lytic activity, which is shown to be induced by the culture conditions, most likely
by growth factors such as IL-2. This strongly suggests that TCR-y/b does not
play a role in target cell recognition in MHC-nonrestricted cytotoxicity. The
anti-TCR--y/b antibody can specifically induce cytotoxic activity in clones
expressing the receptor, but in addition inhibit growth factor induced cytotox-
icity, which indicates a regulatory role of the TCR-y/b/CD3 complex in MHG
nonrestricted cytotoxicity.
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